Intra-Cellular Stock Executives

ITCI
 Stock
  

USD 55.17  1.91  3.35%   

Intra-Cellular Ther employes about 512 people. The company is managed by 19 executives with total tenure of roughly 118 years, averaging almost 6.0 years of service per executive having 26.95 employees per reported executive. Examination of Intra-Cellular Ther management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Intra-Cellular Ther future performance.
Please see Risk vs Return Analysis.
  
Refresh
  Sharon Mates  Chairman
Co-Founder, Chairman, CEO and Pres
  Lawrence Wennogle  President
Vice President of Drug Discovery
  Suresh Durgam  President
Senior Vice President Late Stage Clinical Development and Medical Affairs

Intra-Cellular Ther Return on Sales

(3.66)

Share

Intra-Cellular Ther Management Team Effectiveness

Intra-Cellular Ther has return on total asset (ROA) of (29.58) % which means that it has lost $29.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (52.87) %, meaning that it created substantial loss on money invested by shareholders. Intra-Cellular Ther management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -57.36. The current Return on Average Assets is estimated to decrease to -0.52. Intra-Cellular Ther Asset Turnover is most likely to slightly decrease in the upcoming years. The last year's value of Asset Turnover was reported at 0.14. The current Tangible Assets Book Value per Share is estimated to increase to 6.98, while Total Assets are projected to decrease to roughly 435.4 M.

Intra-Cellular Ther Quarterly Total Assets

868.58 Million

Share
The current Issuance Purchase of Equity Shares is estimated to increase to about 11.8 M, while Weighted Average Shares is projected to decrease to roughly 66.4 M.

Intra-Cellular Ther Workforce Comparison

Intra-Cellular Ther is currently regarded as number one stock in number of employees category among related companies. The total workforce of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 1.1 Million. Intra-Cellular Ther adds roughly 512 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.

Intra-Cellular Ther Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intra-Cellular Ther insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intra-Cellular Ther's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Intra-Cellular Ther insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Intra-Cellular Ther Benchmark Summation

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Lowest and highest values over a specified period plots line showing minimum and maximum value of Intra-Cellular Ther price series.
.

Intra-Cellular Ther Notable Stakeholders

An Intra-Cellular Ther stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Intra-Cellular Ther often face trade-offs trying to please all of them. Intra-Cellular Ther's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Intra-Cellular Ther's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Allen Fienberg - Co-Founder and VP of Bus. Devel.Profile
Sharon Mates - Co-Founder, Chairman, CEO and PresProfile
Lawrence Wennogle - Vice President of Drug DiscoveryProfile
Suresh Durgam - Senior Vice President Late Stage Clinical Development and Medical AffairsProfile
Robert Davis - Senior Vice President and Chief Scientific OfficerProfile
Mark Neumann - Executive Vice President Chief Commercial OfficerProfile
Andrew Satlin - Executive Vice President and Chief Medical OfficerProfile
Juan Sanchez - Vice President - Corporate Communications and Investor RelationsProfile
John Bardi - Senior Vice President - Market Access, Policy and Government AffairsProfile
Michael Olchaskey - Senior Vice President Head of Regulatory AffairsProfile
Lawrence Hineline - Vice President and CFOProfile
Michael Halstead - Sr. VP, General Counsel and SecretaryProfile
Christopher Alafi - DirectorProfile
Michael Rawlins - DirectorProfile
Robert Nostrand - Independent DirectorProfile
Richard Lerner - DirectorProfile
Rory Riggs - Independent DirectorProfile
Joel Marcus - DirectorProfile
Kimberly Vanover - VP of Clinical Devel.Profile

About Intra-Cellular Ther Management Performance

The success or failure of an entity such as Intra-Cellular Ther often depends on how effective the management is. Intra-Cellular Ther management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Intra-Cellular management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Intra-Cellular management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Investment(53.16) (57.36) 
Return on Average Assets(0.48) (0.52) 
Return on Average Equity(0.55) (0.59) 
Return on Invested Capital(0.63) (0.65) 
Return on Sales(3.39) (3.66) 
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun for the treatment of Parkinsons disease and heart failure ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
The data published in Intra-Cellular Ther's official financial statements usually reflect Intra-Cellular Ther's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Intra-Cellular Ther. For example, before you start analyzing numbers published by Intra-Cellular accountants, it's critical to develop an understanding of what Intra-Cellular Ther's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Intra-Cellular Ther's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intra-Cellular Ther's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Intra-Cellular Ther's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Intra-Cellular Ther. Please utilize our Beneish M Score to check the likelihood of Intra-Cellular Ther's management to manipulate its earnings.

Intra-Cellular Ther Workforce Analysis

Traditionally, organizations such as Intra-Cellular Ther use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Intra-Cellular Ther within its industry.

Intra-Cellular Ther Manpower Efficiency

Return on Intra-Cellular Ther Manpower

Revenue Per Employee176.6 K
Revenue Per Executive4.4 M
Net Loss Per Employee598.7 K
Net Loss Per Executive15 M
Working Capital Per Employee783.5 K
Working Capital Per Executive21.1 M
Today, most investors in Intra-Cellular Ther Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Intra-Cellular Ther's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Intra-Cellular Ther per employee as a starting point in their analysis.

Per Employee

Intra-Cellular Ther Per Employee Growth Over Time

Net Income Per Employee

(598,744)

Share
Intra-Cellular Ther Net Income Per Employee is most likely to increase significantly in the upcoming years. The last year's value of Net Income Per Employee was reported at (554,933)

Revenue Per Employee

176,600

Share
Intra-Cellular Ther Revenue Per Employee is most likely to decrease significantly in the upcoming years. The last year's value of Revenue Per Employee was reported at 163,678
Please see Risk vs Return Analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.